I Core Connect Inc. ICCT
We take great care to ensure that the data presented and summarized in this overview for iCoreConnect Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ICCT
Top Purchases
Top Sells
About ICCT
iCoreConnect Inc., a cloud-based software and technology company, provides cloud-based software products for the healthcare sector in the United States. The company's products include iCoreRx, a compliant electronic prescription software; iCoreExchange, a software as a service (SaaS) email solution that allows doctors to send and receive secure email with attachments to and from other healthcare professionals, patients, and referrals; iCoreCodeGenius that provides the coding standards for the 10th revision of the international classification of diseases and related health problems; and iCoreVerify, a compliant SaaS solution that allows practices to verify patient insurance benefits automatically and on-demand. Its products also comprise iCoreHuddle and iCoreHuddle+, a tool to instantly reveal the revenue potential of each patient; iCoreCloud, a compliant and automated backup solution, which offers customers to back up their on-premise servers and computers to the cloud; iCorePay, a patient payment processing solutions for payment and revenue cycle tracking; iCoreSecure, an encrypted email to protect personal and financial data; and iCoreIT, an IT managed services. The company was formerly known as iMedicor, Inc. and changed its name to iCoreConnect Inc. in June 2017. iCoreConnect Inc. was founded in 1992 and is headquartered in Ocoee, Florida.
Insider Transactions at ICCT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 01
2023
|
Kevin Patrick Mc Dermott |
BUY
Grant, award, or other acquisition
|
Direct |
196,880
+39.87%
|
-
|
Jul 01
2023
|
Robert P Mc Dermott CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
291,492
+1.29%
|
-
|
Jul 01
2023
|
Harry Joseph Travis |
BUY
Grant, award, or other acquisition
|
Direct |
262,506
+36.84%
|
-
|
Jul 01
2023
|
Joseph Gitto |
BUY
Grant, award, or other acquisition
|
Direct |
97,983
+50.0%
|
-
|
Jul 01
2023
|
Archit Shah CFO |
BUY
Grant, award, or other acquisition
|
Direct |
145,746
+26.18%
|
-
|
Apr 14
2023
|
Archit Shah CFO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+42.99%
|
-
|
Apr 14
2023
|
Muralidar Chakravarthi CTO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+8.38%
|
-
|
Apr 14
2023
|
David A. Fidanza CIO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+11.48%
|
-
|
Apr 11
2023
|
Jeff Wayne Stellinga COO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+1.91%
|
-
|
Mar 13
2023
|
Robert P Mc Dermott CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+0.23%
|
-
|
Mar 13
2023
|
Jeff Wayne Stellinga COO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+0.49%
|
-
|
Feb 08
2023
|
Kevin Patrick Mc Dermott |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$0
$0.1 P/Share
|
Jan 31
2023
|
Robert P Mc Dermott CEO & President |
BUY
Open market or private purchase
|
Direct |
815,452
+3.59%
|
$0
$0.1 P/Share
|
Jan 15
2023
|
Jeff Wayne Stellinga COO |
BUY
Open market or private purchase
|
Direct |
500,000
+4.75%
|
$0
$0.1 P/Share
|
Jan 05
2023
|
Robert P Mc Dermott CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
4,000,000
+15.95%
|
-
|
Dec 31
2022
|
Robert A De Santi |
BUY
Grant, award, or other acquisition
|
Direct |
275,000
+2.19%
|
-
|
Dec 08
2022
|
Robert P Mc Dermott CEO & President |
BUY
Open market or private purchase
|
Direct |
20,790
+0.12%
|
$0
$0.09 P/Share
|
Dec 06
2022
|
Robert A De Santi |
BUY
Open market or private purchase
|
Direct |
265,171
+2.16%
|
$0
$0.08 P/Share
|
Nov 23
2022
|
Robert P Mc Dermott CEO & President |
BUY
Open market or private purchase
|
Direct |
32,090
+0.19%
|
$0
$0.08 P/Share
|
Nov 23
2022
|
Archit Shah CFO |
BUY
Open market or private purchase
|
Direct |
6,300
+8.81%
|
$0
$0.08 P/Share
|